[Dynamics of clinical and biological indices of the asthenic symptom-complex during immunotropic therapy of patients with schizophrenia].
Observational study · 2018
- What was studied
- 43 men aged 20–55 with schizophrenia and asthenic symptoms
- Main finding
- Adjunctive Bestim was associated with reduced asthenic symptom scores during complex psychiatric treatment.
Affective-asthenic subgroup · 32.5%
Reported findings and study design
43 men aged 20–55 with schizophrenia and asthenia; clinical assessments before treatment and 5/30 days afterward.
Population or model 43 men aged 20–55 with schizophrenia and asthenic symptoms
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Affective-asthenic subgroup | 32.5% | |
| Asthenic-negative subgroup | 67.5% | |
| Later symptom regression in asthenic-negative subgroup | More marked in the authors’ comparison | p<0.001 |
The percentages describe symptom categories, not responder rates.
Source for these results ↗ · Reviewed 2026-10-29
Study limitations and source details
Study limitations
- An untreated concurrent control and random allocation are not established by the abstract; improvement cannot be attributed to Bestim alone.
- Full methods, reporting completeness and independent replication remain to be appraised.
Source details
Original journal report
Primary citation and indexed abstract reviewed through Europe PMC. Full article not appraised.
Abstract reviewed
Sources checked
Citation
Yakimets AV, Zozulya SA, Oleichik IV, Klyushnik TP. [Dynamics of clinical and biological indices of the asthenic symptom-complex during immunotropic therapy of patients with schizophrenia]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova · PMID 29652309
Study source ↗ · DOI 10.17116/jnevro20181183170-76 · Bibliography entry · Link to this summary